Current Alzheimer Research
Title:ERRATUM
Volume: 9 Issue: 9
Export Options
About this article
Cite this article as:
ERRATUM, Current Alzheimer Research 2012; 9 (9) . https://dx.doi.org/10.2174/156720512803569019
DOI https://dx.doi.org/10.2174/156720512803569019 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
30 September, 2024
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Guest Editor(s): Mohammad Amjad Kamal
Related Journals
9
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chemistry of Galanthamine. Classical Synthetic Methods and Comprehensive Study on its Analogues
Mini-Reviews in Medicinal Chemistry Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Patent Selections:
Current Biomarkers (Discontinued) Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry The Antiplatelet Drug Target in Atherosclerotic Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Current Pharmaceutical Biotechnology Development and Applications of Non-HIV-Based Lentiviral Vectors in Neurological Disorders
Current Gene Therapy Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer’s Disease Mice
Current Alzheimer Research Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research Lipids as a Target for Drugs Modulating Multidrug Resistance of Cancer Cells
Current Drug Targets Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment
Current Alzheimer Research Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Commentary: Stephen William Hawking (8 January 1942 – 14 March 2018)
CNS & Neurological Disorders - Drug Targets Immunotherapy for Conformational Diseases
Current Pharmaceutical Design “Micromanaging” Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies
Current Neurovascular Research